Dual Value Creation: Revenue Growth + PPS Windfall
Post# of 8610

Viant Medical’s partnership with BIEL is poised to generate substantial operational revenue through manufacturing, distribution, and product modernization. But that’s just the beginning.
The real financial windfall for Viant lies in the exponential profit potential tied to BIEL’s rising price per share (PPS).
By accumulating up to 1.2 billion shares at ultra-low prices ($0.0001–$0.0002), Viant positions itself for outsized equity returns.
Every milestone—FDA expansion, insurance reimbursement, retail adoption—has the power to compound Viant’s stake value dramatically.
This isn’t just revenue—it’s equity arbitrage, where Viant’s cost basis remains fixed while BIEL’s PPS climbs with each success.
And here’s the kicker:
$40 million in BIEL tax-loss carryforwards act as a profit shield, allowing Viant to realize gains with minimal tax exposure.
This creates a tax-efficient, asymmetric upside—Viant helps BIEL scale, and in return, its equity stake becomes a high-leverage asset.
In short: Viant builds the engine. BIEL hits the gas. Viant’s PPS-linked profits could far exceed any manufacturing margin.

